主动脉疾病家族史对复杂主动脉瘤开窗与分支腔内修复术结局的影响
本研究回顾性分析美国主动脉研究联盟10项前瞻性、非随机、医生发起、研究器械豁免研究中的连续患者(2005-2022年),评估主动脉疾病家族史对复杂主动脉瘤开窗与分支腔内修复术(FB-EVAR)结局的影响。共纳入2355例患者(有家族史427例,无家族史1928例),结果显示家族史对30天及中期结局无影响。
要点
- 有家族史者更常有开放腹主动脉修复史,较少有腔内修复史(p < .050)。
- 有与无家族史者30天死亡率(4% vs. 2%;p = .12)和主要不良事件(12% vs. 12%;p = .89)无统计学显著差异。
- 两组3年生存率估计分别为71%(95%CI 67-78%)和71%(95%CI 68-74%)(p = .74),无统计学显著差异。
核心结论
- 主动脉疾病家族史对复杂主动脉瘤FB-EVAR的30天或中期结局无影响。
- 在未发现遗传触发主动脉疾病的情况下,复杂主动脉瘤的治疗选择应基于临床风险和患者解剖,而非主动脉疾病家族史。
研究设计与样本
- 回顾性审查美国主动脉研究联盟数据库中10项正在进行的、前瞻性、非随机、医生发起、研究器械豁免研究中连续入组的患者(2005-2022年),以评估FB-EVAR。
- 共2901例患者接受FB-EVAR,最终分析纳入2355例(81.2%):有主动脉疾病家族史427例(18.1%),无家族史1928例(81.9%)。
- 排除确诊遗传触发主动脉疾病的患者;按任何亲属中是否存在任何主动脉疾病家族史进行分层。
主要发现
- 有家族史者更常有既往开放腹主动脉修复史,较少有既往腔内动脉瘤修复史(p < .050)。
- 有与无家族史者30天死亡率分别为4% vs. 2%(p = .12),主要不良事件分别为12% vs. 12%(p = .89),均无统计学显著差异。
- 有与无家族史者3年生存率估计分别为71%(95%CI 67-78%)和71%(95%CI 68-74%)(p = .74),无统计学显著差异。
- 两组免于二次干预和动脉瘤囊扩张也无统计学显著差异。
临床怎么用
- 在未发现遗传触发主动脉疾病的情况下,复杂主动脉瘤的治疗选择应基于临床风险和患者解剖,而非主动脉疾病家族史。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The clinical significance of family history (FH) of aortic disease on the outcomes of fenestrated and branched endovascular aneurysm repair (FB-EVAR) has not been well described. This study aimed to assess how FH of aortic disease affects outcomes following FB-EVAR for complex aortic aneurysms (CAAs). METHODS: This study retrospectively reviewed the clinical data of consecutive patients enrolled in 10 ongoing, prospective, non-randomised, physician sponsored, investigational device exemption studies to evaluate FB-EVAR (2005 - 2022) in the United States Aortic Research Consortium database. Patients were stratified by presence or absence of FH of any aortic disease in any relative. Patients with confirmed genetically triggered aortic diseases were excluded. Primary outcomes were 30 day major adverse events (MAEs) and late survival. Secondary outcomes included late secondary interventions and aneurysm sac enlargement. RESULTS: During the study period, 2 901 patients underwent FB-EVAR. A total of 2 355 patients (81.2%) were included in the final analysis: 427 (18.1%) with and 1 928 (81.9%) without a FH of aortic disease. Patient demographics, clinical characteristics, and aneurysm extent were similar between the groups. Patients with a FH of aortic disease more frequently had prior open abdominal aortic repair, but less frequently had prior endovascular aneurysm repair (p < .050). There were no statistically significant differences in 30 day mortality (4% vs. 2%; p = .12) and MAEs (12% vs. 12%; p = .89) for patients with or without a FH of aortic disease. Three year survival estimates were 71% (95% confidence interval [CI] 67 - 78%) and 71% (95% CI 68 - 74%), respectively (p = .74). Freedom from secondary intervention and aneurysm sac enlargement were also not statistically significantly different between groups. CONCLUSION: A FH of aortic disease had no impact on 30 day or midterm outcomes of FB-EVAR of CAAs. In the absence of an identified genetically triggered aortic disease, treatment selection for CAAs should be based on clinical risk and patient anatomy rather than FH of aortic disease.
引用
- Sulzer TAL, Mesnard T, Schanzer A, et al. Effect of Family History of Aortic Disease on Outcomes of Fenestrated and Branched Endovascular Aneurysm Repair of Complex Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2024. PMID: 38750880. doi:10.1016/j.ejvs.2024.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。